Workflow
ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order
Prnewswireยท2025-09-30 20:30

Core Viewpoint - ESSA Pharma Inc. is progressing with its Business Combination Agreement with XenoTherapeutics Inc., receiving an amended Interim Order from the Supreme Court of British Columbia to facilitate the transaction [1][2]. Group 1: Transaction Details - The amended Interim Order approves the date for ESSA's Special Meeting on October 3, 2025, and sets the deadline for dissent notices on October 1, 2025 [2]. - The Court hearing for the approval of the Arrangement is scheduled for October 7, 2025, with a deadline for responses from attendees by October 3, 2025 [2]. - ESSA's Special Meeting will be held online at 2:00 p.m. (Pacific Time) on October 3, 2025, via a live interactive webcast [3]. Group 2: Company Background - ESSA Pharma Inc. focuses on developing novel therapies for prostate cancer treatment [4]. - XenoTherapeutics Inc. is a non-profit biotechnology company dedicated to advancing xenotransplantation through research and public education [5].